The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in phase III randomized trial: JCOG0602.
TAKASHI ONDA
No relevant relationships to disclose
Hiroyuki Yoshikawa
No relevant relationships to disclose
Taro Shibata
No relevant relationships to disclose
Kenichi Nakamura
No relevant relationships to disclose
Toyomi Satoh
No relevant relationships to disclose
Toshiaki Saito
No relevant relationships to disclose
Takahiro Kasamatsu
No relevant relationships to disclose
Toru Nakanishi
No relevant relationships to disclose
Takayoshi Nogawa
No relevant relationships to disclose
Motoaki Saitou
No relevant relationships to disclose
Kimio Ushijima
No relevant relationships to disclose
Hiroaki Kobayashi
No relevant relationships to disclose
Tadao Takano
No relevant relationships to disclose
Kei Kawana
No relevant relationships to disclose
Harushige Yokota
No relevant relationships to disclose
Masashi Takano
No relevant relationships to disclose
Nobuhiro Takeshima
No relevant relationships to disclose
Nobuo Yaegashi
No relevant relationships to disclose
Ikuo Konishi
No relevant relationships to disclose
Toshiharu Kamura
No relevant relationships to disclose